AngioDynamics, Inc. (ANGO) return on equity (ROE)

Return on equity · fiscal 2026
-21.5%

AngioDynamics, Inc. (ANGO) earned a return on equity of -21.5% in fiscal 2026 (the year ended May 31, 2026). That is 2.9 percentage points lower than the -18.6% of fiscal 2025. Figures as of 18 Nov 2026, 00:19 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2026
-21.5%
Change on fiscal 2025
−2.9 pts
Highest on record
10.0%fiscal 2019
Lowest on record
-89.7%fiscal 2024
Fiscal years on record
172010–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

AngioDynamics, Inc. return on equity (ROE), in more detail

Across the 17 fiscal years on record (2010–2026), the highest was 10.0% in fiscal 2019 and the lowest -89.7% in fiscal 2024. The fiscal 2026 figure is higher than in 13% of the 16 earlier fiscal years on record, whose median is -0.8%.

History · 17 fiscal years

Return on equity by fiscal year

AngioDynamics, Inc. return on equity (ROE), year by year

AngioDynamics, Inc. (ANGO) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2026-21.5% 2.9 pts down
2025-18.6% 71.1 pts up
2024-89.7% 75.8 pts down
2023-13.9% 7.6 pts down
2022-6.3% 0.9 pts up
2021-7.2% 29.5 pts up
2020-36.7% 46.6 pts down
201910.0% 7.0 pts up
20183.0% 2.0 pts up
20171.0% 9.6 pts up
2016-8.6% 8.0 pts down
2015-0.6% 1.1 pts down
20140.4% 0.6 pts up
2013-0.2% 0.8 pts up
2012-1.0% 3.0 pts down
20112.0% 1.2 pts down
20103.1%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on ANGO

AngioDynamics, Inc., figure by figure

AngioDynamics, Inc. (ANGO) overview: price, valuation and scorecard

AngioDynamics, Inc. return on equity (ROE): questions and answers

What is AngioDynamics, Inc.'s return on equity?

AngioDynamics, Inc. (ANGO) earned a return on equity of -21.5% in fiscal 2026 (the year ended May 31, 2026). That is 2.9 percentage points lower than the -18.6% of fiscal 2025.

Is AngioDynamics, Inc.'s return on equity high or low compared with its own history?

The fiscal 2026 figure is higher than in 13% of the 16 earlier fiscal years on record, whose median is -0.8%.

What are the highest and lowest return on equity figures on record for AngioDynamics, Inc.?

Across the 17 fiscal years on record (2010–2026), the highest was 10.0% in fiscal 2019 and the lowest -89.7% in fiscal 2024.

How is AngioDynamics, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “AngioDynamics, Inc. (ANGO) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/ANGO/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.